BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AirXpanders, Inc. Announces Expansion of Leadership Team


4/17/2012 11:40:06 AM

PALO ALTO, CA--(Marketwire - April 16, 2012) - AirXpanders Inc., a company developing technology to address current unmet needs for patients who require tissue expansion for breast reconstruction surgery, today announced that it has expanded its senior management team with new hires to help the company prepare for a successful launch of AeroForm in early 2013.

"We are honored to attract such exceptionally talented, experienced, and successful professionals to AirXpanders to complement our growing leadership team as we prepare for a potential U.S. launch of AeroForm early next year," says Scott Dodson, President and CEO of AirXpanders. "Enrollment in the pivotal XPAND study of our AeroForm tissue expansion device in mastectomy patients going through breast reconstruction is on track. As the study continues, we are working diligently to prepare our regulatory submission to the FDA and ensure that we have the proper quality systems in place for a successful commercial rollout. These high caliber team members will play a crucial part in the growth and expansion of our company and will add to our commitment to quality and excellence."

Naghmeh Nouri has been named Senior Director of Quality and Regulatory, John Lai joins the company as Director of Finance, and Tony Morefield joins AirXpanders as Senior Director of Operations.

Nouri joins AirXpanders with 28 years of experience as a scientist and quality expert. She was previously VP of Quality and Regulatory at Asante Solutions and VP of Quality and Regulatory at Health Hero Network where she led all activities for quality and regulatory implementation, product maintenance, and secured a CE Mark, 510K and managed a new series of FDA regulations. Nouri holds both an M.S. and a B.S. from the Rutgers Electrical Engineering Honors Program.

Lai, a seasoned financial services professional, joins AirXpanders after 14 years of experience in the field of accounting and finance. Previously, John served as Director of Accounting and Finance Services for Montgomery Professional Services and is an expert in financial services for medical device companies. John holds a B.A. in Accounting from Seattle University.

Morefield has over 15 years of experience in the medical device and aerospace industry with a focus on transitioning innovative technologies through late stage development into full scale manufacturing. He most recently held the position of Senior Director of Manufacturing and Engineering at Avantis Medical Systems where he was responsible for ramping operations during the course of clinical studies and into full commercialization with the eventual transition into off-shore manufacturing. Morefield holds a B.S. from the University of Oregon.

About AirXpanders

AirXpanders Inc. (www.airxpanders.com), is a tissue-expansion company focused on the area of breast cancer reconstruction. By employing a revolutionary patient-controlled expander, activated by a wireless remote control, the often painful process of recovering one's feminine shape after cancer can potentially be eased with this needle-free technology that is easy to use and may enable the patient to proceed to a permanent implant much faster than the current standard-of-care. At this time, AirXpanders' products are not cleared or approved for sale. AirXpanders is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Shalon Ventures.


Media Contact
Erich Sandoval
Lazar Partners Ltd.
esandoval@lazarpartners.com
917-497-2867

Company Contact
Scott Dodson
President & CEO
sdodson@airxpanders.com
650-390-9008



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES